All In Biotech

Drug Trial Radar · NCT06692452

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

A Phase II Study of Tazemetostat in Combination With CHOP for Previously Untreated T Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Dec 24, 2024

Primary completion

Oct 1, 2027

Study completion Oct 1, 2032

Sponsor

Lead sponsor
Eric Jacobsen, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ipsen
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL). The name of the study drugs involved in this study are: * Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2)) * Standard of care CHOP therapy: * Cyclophosphamide (a type of alkylating agent) * Doxorubicin (a type of anthracycline antibiotic) * Vincristine (a type of vinca alkaloid) * Prednisone (a type of corticosteroid) * Standard of care BEAM conditioning regimen for autologous stem cell transplant: * Carmustine (a type of alkylating agent) * Etoposide (a type of Topoisomerase II inhibitor) * Cytarabine (a type of antineoplastic) * Melphalan (a type of alkylating agent)

Conditions

  • Lymphoma
  • Peripheral T Cell Lymphoma
  • Angioimmunoblastic T-cell Lymphoma
  • Enteropathy-Associated T-Cell Lymphoma
  • Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Interventions

  • TazemetostatDrug

    EZH2 inhibitor, 200 mg tablet, taken orally per protocol.

  • DoxorubicinDrug

    Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.

  • VincristineDrug

    Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.

  • PrednisoneDrug

    Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.

  • CytoxanDrug

    Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.

  • CarmustineDrug

    Alkylating agent, 100 mg single dose vials, via intravenous (into the vein) infusion per institutional standard of care.

  • EtoposideDrug

    Topoisomerase II inhibitor, 100mg single dose vial, via intravenous (into the vein) infusion per institutional standard of care.

  • CytarabineDrug

    Antineoplastic, 20mg single dose vial, via intravenous, intrathecal, or subcutaneous injection per institutional standard of care

  • MelphalanDrug

    Alkylating agent, 90 mg multi-dose vial, via parenteral infusion per institutional standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate (CRR)Time frame: Up to 18 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.